Chemokine β-7 variants
AssigneesHuman Genome Sciences, Inc., Beatson Institute for Cancer Research
InventorsTheodora W. Salcedo, Vikram P. Patel, Robert John Benjamin Nibbs, Gerard John Graham
Life of this patent
Estimating the term…
Abstract
The present invention relates to deletion and substitution mutant polypeptides of human chemokine β-7 (Ckβ-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ckβ-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ckβ-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.
Claims20
An isolated protein comprising the amino acid sequence of SEQ ID NO:16.
An isolated chemokine β-7 variant polypeptide selected from the group consisting of:
- (a) a polypeptide at least 90% identical to SEQ ID NO:16;
- and
- (b) a polypeptide comprising the amino acid sequence of SEQ ID NO:16 except for up to ten amino acid substitutions
- wherein said variant polypeptide inhibits the calcium flux induced in eosinophils by eotaxin, MCP-4, RANTES, MCP-3, eotaxin-2.
Dependencies are inferred from the claim text.